Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids
There are a number of approved therapeutics for the management of alcohol dependence, which might also convey the potential as smoking cessation aids. The present study investigated the effect of a few of these therapeutics and potential candidates (non‐peptide vasopressin V1b antagonists) on the ex...
Gespeichert in:
| Veröffentlicht in: | Addiction biology 2016-03, Vol.21 (2), p.234-241 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 241 |
|---|---|
| container_issue | 2 |
| container_start_page | 234 |
| container_title | Addiction biology |
| container_volume | 21 |
| creator | Goutier, Wouter Kloeze, Margreet McCreary, Andrew C. |
| description | There are a number of approved therapeutics for the management of alcohol dependence, which might also convey the potential as smoking cessation aids. The present study investigated the effect of a few of these therapeutics and potential candidates (non‐peptide vasopressin V1b antagonists) on the expression of nicotine‐induced behavioral sensitization in Wistar rats. The following compounds were included in this evaluation: rimonabant, bupropion, topiramate, acamprosate, naltrexone, mecamylamine, nelivaptan (SSR‐149415, V1b antagonist) and two novel V1b antagonists. Following the development of nicotine‐induced locomotor sensitization and a withdrawal period, the expression of sensitization was assessed in the presence of one of the examined agents given 30 minutes prior to the nicotine challenge injection. Acamprosate, naltrexone, rimonabant, mecamylamine, nelivaptan and V1b antagonist ‘compound 2′ significantly antagonized the expression of nicotine‐induced sensitization. Whereas topiramate showed a trend for effects, the V1b antagonist ‘compound 1′ did not show any significant effects. Bupropion failed to block sensitization but increased activity alone and was therefore tested in development and cross‐sensitization studies. Taken together, these findings provide pre‐clinical evidence that these molecules attenuated the expression of nicotine‐induced sensitization and should be further investigated as putative treatments for nicotine addiction. Moreover, V1b antagonists should be further investigated as a potential novel smoking cessation aid.
There are a number of approved therapeutics for the management of alcohol dependence, which might also convey potential as smoking cessation aids. The present study investigated the effect of a few of these drugs and potential novel therapeutic‐candidates (i.e., non‐peptide vasopressin V1b antagonists) on the expression of nicotine‐induced behavioral sensitization in Wistar rats. The findings provide pre‐clinical evidence that these molecules attenuated the expression of nicotine‐induced sensitization, raising interest as putative treatments for nicotine dependence. |
| doi_str_mv | 10.1111/adb.12190 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1776668333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1776668333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4240-8e3f191ba92692672849089708a13ddcd1801da0d37d9440621bd1fd5adcf4e3</originalsourceid><addsrcrecordid>eNqFkU1LHTEUhkNpqR914R-QQDe6GE0mM_nozo-qBbGKgstwbpLxRmcm12QGvf31xnvVhVA8BHIWz_vA4UVok5JdmmcP7GSXllSRL2iVMq4Kygn5-rLXdcFLWq-gtZTuCKGlqNl3tFLWjAjJxSqannsTBt-7wvd2NM7iNpjQhSFEnFyf_OD_weBD_wvPphA7MKENt95Ai6GHdp5cwo9-mGIDvfUWBodTF-59f4uNS2kRxeBt-oG-NdAmt_H6r6Pr49_Xh6fF2d-TP4f7Z4WpyooU0rGGKjoBVfL8RCkrRaQSRAJl1hpLJaEWiGXCqqoi-bqJpY2twZqmcmwdbS-1sxgeRpcG3flkXNtC78KYNBWCcy5Zns9RLmtOKlVm9OcH9C6MMd-_oIQQUimSqZ0lZWJIKbpGz6LvIM41JfqlKJ2L0ouiMrv1ahwnnbPv5FszGdhbAo--dfP_m_T-0cGbslgmfBrc03sC4r3OPlHrm_MTfXpzWZGryyt9wZ4BXv-sAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1767778990</pqid></control><display><type>article</type><title>Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids</title><source>MEDLINE</source><source>Wiley Blackwell Single Titles</source><creator>Goutier, Wouter ; Kloeze, Margreet ; McCreary, Andrew C.</creator><creatorcontrib>Goutier, Wouter ; Kloeze, Margreet ; McCreary, Andrew C.</creatorcontrib><description>There are a number of approved therapeutics for the management of alcohol dependence, which might also convey the potential as smoking cessation aids. The present study investigated the effect of a few of these therapeutics and potential candidates (non‐peptide vasopressin V1b antagonists) on the expression of nicotine‐induced behavioral sensitization in Wistar rats. The following compounds were included in this evaluation: rimonabant, bupropion, topiramate, acamprosate, naltrexone, mecamylamine, nelivaptan (SSR‐149415, V1b antagonist) and two novel V1b antagonists. Following the development of nicotine‐induced locomotor sensitization and a withdrawal period, the expression of sensitization was assessed in the presence of one of the examined agents given 30 minutes prior to the nicotine challenge injection. Acamprosate, naltrexone, rimonabant, mecamylamine, nelivaptan and V1b antagonist ‘compound 2′ significantly antagonized the expression of nicotine‐induced sensitization. Whereas topiramate showed a trend for effects, the V1b antagonist ‘compound 1′ did not show any significant effects. Bupropion failed to block sensitization but increased activity alone and was therefore tested in development and cross‐sensitization studies. Taken together, these findings provide pre‐clinical evidence that these molecules attenuated the expression of nicotine‐induced sensitization and should be further investigated as putative treatments for nicotine addiction. Moreover, V1b antagonists should be further investigated as a potential novel smoking cessation aid.
There are a number of approved therapeutics for the management of alcohol dependence, which might also convey potential as smoking cessation aids. The present study investigated the effect of a few of these drugs and potential novel therapeutic‐candidates (i.e., non‐peptide vasopressin V1b antagonists) on the expression of nicotine‐induced behavioral sensitization in Wistar rats. The findings provide pre‐clinical evidence that these molecules attenuated the expression of nicotine‐induced sensitization, raising interest as putative treatments for nicotine dependence.</description><identifier>ISSN: 1355-6215</identifier><identifier>EISSN: 1369-1600</identifier><identifier>DOI: 10.1111/adb.12190</identifier><identifier>PMID: 25307867</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Analysis of Variance ; Animals ; Antidiuretic Hormone Receptor Antagonists - pharmacology ; Bupropion - pharmacology ; Cessation aids ; Dose-Response Relationship, Drug ; Fructose - analogs & derivatives ; Fructose - pharmacology ; Indoles - pharmacology ; Male ; Motor Activity - drug effects ; Naltrexone - pharmacology ; Nicotine ; Nicotine - pharmacology ; nicotine behavioral sensitization ; Nicotinic Agonists - pharmacology ; pharmacological strategies ; Pyrrolidines - pharmacology ; Rats, Wistar ; Smoking cessation ; Taurine - analogs & derivatives ; Taurine - pharmacology ; Tobacco Use Cessation Products</subject><ispartof>Addiction biology, 2016-03, Vol.21 (2), p.234-241</ispartof><rights>2014 Society for the Study of Addiction</rights><rights>2014 Society for the Study of Addiction.</rights><rights>2016 Society for the Study of Addiction</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4240-8e3f191ba92692672849089708a13ddcd1801da0d37d9440621bd1fd5adcf4e3</citedby><cites>FETCH-LOGICAL-c4240-8e3f191ba92692672849089708a13ddcd1801da0d37d9440621bd1fd5adcf4e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fadb.12190$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fadb.12190$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25307867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goutier, Wouter</creatorcontrib><creatorcontrib>Kloeze, Margreet</creatorcontrib><creatorcontrib>McCreary, Andrew C.</creatorcontrib><title>Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids</title><title>Addiction biology</title><addtitle>Addiction Biology</addtitle><description>There are a number of approved therapeutics for the management of alcohol dependence, which might also convey the potential as smoking cessation aids. The present study investigated the effect of a few of these therapeutics and potential candidates (non‐peptide vasopressin V1b antagonists) on the expression of nicotine‐induced behavioral sensitization in Wistar rats. The following compounds were included in this evaluation: rimonabant, bupropion, topiramate, acamprosate, naltrexone, mecamylamine, nelivaptan (SSR‐149415, V1b antagonist) and two novel V1b antagonists. Following the development of nicotine‐induced locomotor sensitization and a withdrawal period, the expression of sensitization was assessed in the presence of one of the examined agents given 30 minutes prior to the nicotine challenge injection. Acamprosate, naltrexone, rimonabant, mecamylamine, nelivaptan and V1b antagonist ‘compound 2′ significantly antagonized the expression of nicotine‐induced sensitization. Whereas topiramate showed a trend for effects, the V1b antagonist ‘compound 1′ did not show any significant effects. Bupropion failed to block sensitization but increased activity alone and was therefore tested in development and cross‐sensitization studies. Taken together, these findings provide pre‐clinical evidence that these molecules attenuated the expression of nicotine‐induced sensitization and should be further investigated as putative treatments for nicotine addiction. Moreover, V1b antagonists should be further investigated as a potential novel smoking cessation aid.
There are a number of approved therapeutics for the management of alcohol dependence, which might also convey potential as smoking cessation aids. The present study investigated the effect of a few of these drugs and potential novel therapeutic‐candidates (i.e., non‐peptide vasopressin V1b antagonists) on the expression of nicotine‐induced behavioral sensitization in Wistar rats. The findings provide pre‐clinical evidence that these molecules attenuated the expression of nicotine‐induced sensitization, raising interest as putative treatments for nicotine dependence.</description><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Antidiuretic Hormone Receptor Antagonists - pharmacology</subject><subject>Bupropion - pharmacology</subject><subject>Cessation aids</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fructose - analogs & derivatives</subject><subject>Fructose - pharmacology</subject><subject>Indoles - pharmacology</subject><subject>Male</subject><subject>Motor Activity - drug effects</subject><subject>Naltrexone - pharmacology</subject><subject>Nicotine</subject><subject>Nicotine - pharmacology</subject><subject>nicotine behavioral sensitization</subject><subject>Nicotinic Agonists - pharmacology</subject><subject>pharmacological strategies</subject><subject>Pyrrolidines - pharmacology</subject><subject>Rats, Wistar</subject><subject>Smoking cessation</subject><subject>Taurine - analogs & derivatives</subject><subject>Taurine - pharmacology</subject><subject>Tobacco Use Cessation Products</subject><issn>1355-6215</issn><issn>1369-1600</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1LHTEUhkNpqR914R-QQDe6GE0mM_nozo-qBbGKgstwbpLxRmcm12QGvf31xnvVhVA8BHIWz_vA4UVok5JdmmcP7GSXllSRL2iVMq4Kygn5-rLXdcFLWq-gtZTuCKGlqNl3tFLWjAjJxSqannsTBt-7wvd2NM7iNpjQhSFEnFyf_OD_weBD_wvPphA7MKENt95Ai6GHdp5cwo9-mGIDvfUWBodTF-59f4uNS2kRxeBt-oG-NdAmt_H6r6Pr49_Xh6fF2d-TP4f7Z4WpyooU0rGGKjoBVfL8RCkrRaQSRAJl1hpLJaEWiGXCqqoi-bqJpY2twZqmcmwdbS-1sxgeRpcG3flkXNtC78KYNBWCcy5Zns9RLmtOKlVm9OcH9C6MMd-_oIQQUimSqZ0lZWJIKbpGz6LvIM41JfqlKJ2L0ouiMrv1ahwnnbPv5FszGdhbAo--dfP_m_T-0cGbslgmfBrc03sC4r3OPlHrm_MTfXpzWZGryyt9wZ4BXv-sAQ</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>Goutier, Wouter</creator><creator>Kloeze, Margreet</creator><creator>McCreary, Andrew C.</creator><general>Blackwell Publishing Ltd</general><general>John Wiley & Sons, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>7X8</scope><scope>7TK</scope><scope>7U9</scope></search><sort><creationdate>201603</creationdate><title>Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids</title><author>Goutier, Wouter ; Kloeze, Margreet ; McCreary, Andrew C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4240-8e3f191ba92692672849089708a13ddcd1801da0d37d9440621bd1fd5adcf4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Antidiuretic Hormone Receptor Antagonists - pharmacology</topic><topic>Bupropion - pharmacology</topic><topic>Cessation aids</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fructose - analogs & derivatives</topic><topic>Fructose - pharmacology</topic><topic>Indoles - pharmacology</topic><topic>Male</topic><topic>Motor Activity - drug effects</topic><topic>Naltrexone - pharmacology</topic><topic>Nicotine</topic><topic>Nicotine - pharmacology</topic><topic>nicotine behavioral sensitization</topic><topic>Nicotinic Agonists - pharmacology</topic><topic>pharmacological strategies</topic><topic>Pyrrolidines - pharmacology</topic><topic>Rats, Wistar</topic><topic>Smoking cessation</topic><topic>Taurine - analogs & derivatives</topic><topic>Taurine - pharmacology</topic><topic>Tobacco Use Cessation Products</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goutier, Wouter</creatorcontrib><creatorcontrib>Kloeze, Margreet</creatorcontrib><creatorcontrib>McCreary, Andrew C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><jtitle>Addiction biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goutier, Wouter</au><au>Kloeze, Margreet</au><au>McCreary, Andrew C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids</atitle><jtitle>Addiction biology</jtitle><addtitle>Addiction Biology</addtitle><date>2016-03</date><risdate>2016</risdate><volume>21</volume><issue>2</issue><spage>234</spage><epage>241</epage><pages>234-241</pages><issn>1355-6215</issn><eissn>1369-1600</eissn><abstract>There are a number of approved therapeutics for the management of alcohol dependence, which might also convey the potential as smoking cessation aids. The present study investigated the effect of a few of these therapeutics and potential candidates (non‐peptide vasopressin V1b antagonists) on the expression of nicotine‐induced behavioral sensitization in Wistar rats. The following compounds were included in this evaluation: rimonabant, bupropion, topiramate, acamprosate, naltrexone, mecamylamine, nelivaptan (SSR‐149415, V1b antagonist) and two novel V1b antagonists. Following the development of nicotine‐induced locomotor sensitization and a withdrawal period, the expression of sensitization was assessed in the presence of one of the examined agents given 30 minutes prior to the nicotine challenge injection. Acamprosate, naltrexone, rimonabant, mecamylamine, nelivaptan and V1b antagonist ‘compound 2′ significantly antagonized the expression of nicotine‐induced sensitization. Whereas topiramate showed a trend for effects, the V1b antagonist ‘compound 1′ did not show any significant effects. Bupropion failed to block sensitization but increased activity alone and was therefore tested in development and cross‐sensitization studies. Taken together, these findings provide pre‐clinical evidence that these molecules attenuated the expression of nicotine‐induced sensitization and should be further investigated as putative treatments for nicotine addiction. Moreover, V1b antagonists should be further investigated as a potential novel smoking cessation aid.
There are a number of approved therapeutics for the management of alcohol dependence, which might also convey potential as smoking cessation aids. The present study investigated the effect of a few of these drugs and potential novel therapeutic‐candidates (i.e., non‐peptide vasopressin V1b antagonists) on the expression of nicotine‐induced behavioral sensitization in Wistar rats. The findings provide pre‐clinical evidence that these molecules attenuated the expression of nicotine‐induced sensitization, raising interest as putative treatments for nicotine dependence.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25307867</pmid><doi>10.1111/adb.12190</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-6215 |
| ispartof | Addiction biology, 2016-03, Vol.21 (2), p.234-241 |
| issn | 1355-6215 1369-1600 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1776668333 |
| source | MEDLINE; Wiley Blackwell Single Titles |
| subjects | Analysis of Variance Animals Antidiuretic Hormone Receptor Antagonists - pharmacology Bupropion - pharmacology Cessation aids Dose-Response Relationship, Drug Fructose - analogs & derivatives Fructose - pharmacology Indoles - pharmacology Male Motor Activity - drug effects Naltrexone - pharmacology Nicotine Nicotine - pharmacology nicotine behavioral sensitization Nicotinic Agonists - pharmacology pharmacological strategies Pyrrolidines - pharmacology Rats, Wistar Smoking cessation Taurine - analogs & derivatives Taurine - pharmacology Tobacco Use Cessation Products |
| title | Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A14%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nicotine-induced%20locomotor%20sensitization:%20pharmacological%20analyses%20with%20candidate%20smoking%20cessation%20aids&rft.jtitle=Addiction%20biology&rft.au=Goutier,%20Wouter&rft.date=2016-03&rft.volume=21&rft.issue=2&rft.spage=234&rft.epage=241&rft.pages=234-241&rft.issn=1355-6215&rft.eissn=1369-1600&rft_id=info:doi/10.1111/adb.12190&rft_dat=%3Cproquest_cross%3E1776668333%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1767778990&rft_id=info:pmid/25307867&rfr_iscdi=true |